Published: 11 Sep 2024(Updated: 20 Sep 2024)
4 min
4 min read
50

Sustainable dairy innovation: Daisy Lab uses precision fermentation to produce animal-free milk proteins in INFORS HT bioreactors

BioreactorsCustomerMicrobial bioprocess

As demand for sustainable food sources surges, Daisy Lab is revolutionizing dairy production with precision fermentation technology. By using INFORS HT bioreactors, this New Zealand-based startup is producing animal-free milk proteins like whey and casein. Discover how the innovative process at Daisy Labs, now set to scale with EPA approval, is paving the way for a more sustainable future in dairy.

As global demand for sustainable and ethically produced food sources rises, companies like New Zealand-based Daisy Lab are leading the charge in transforming how we think about dairy. Founded in 2021, Daisy Lab has become a pioneer in precision fermentation, producing animal-free milk proteins. Recently, CEO Irina Miller shared how Daisy Lab has leveraged INFORS HT bioreactors to support their groundbreaking work in this field. 


Precision fermentation: The future of dairy 

Co-founder and Chief Scientific Officer, Nikki Freed, highlighted in an interview with RNZ in May 2024, the wide-reaching applications of precision fermentation. While the technology has been historically used for creating products like insulin, vanilla flavoring, and rennet for cheese-making, Daisy Lab’s innovation involves producing milk proteins such as whey, casein, and lactoferrin without the use of animals. Freed emphasized, “Many people don't understand how we're already using precision fermentation in many of the foods that people are already consuming today. What is new is using it for proteins that are traditionally found in milk." 


Powering precision fermentation at Daisy Lab 

At the heart of Daisy Lab's process is the use of INFORS HT bioreactors. Initially, Daisy Lab borrowed two Multifors instruments from an academic group, which allowed them to scale their precision fermentation processes. These small-scale fermenters were pivotal in early trials of producing their animal-free milk proteins. 

Recognizing the need for greater efficiency, Daisy Lab invested in the Minifors 2 bioreactor, sourced from In Vitro Technologies in partnership with INFORS HT. This “small but mighty” bioreactor has since become an essential part of their laboratory setup, contributing to automation and data tracking—two critical elements for scaling precision fermentation. Irina Miller praised the Minifors 2 as a real "workhorse" in their lab, stating"The Minifors 2 has allowed us to streamline our fermentation process and improve the planning, controlling, and analyzing of our bioprocesses.” 


Scaling up with Environmental Protection Authority (EPA) approval 

In a recent milestone, Daisy Lab secured approval from the Environmental Protection Authority (EPA) to scale their production 500-fold. This is a significant leap forward for their goal of supplying animal-free proteins to dairy manufacturers globally. Freed commented that this EPA approval is a crucial step towards the use of larger stainless-steel bioreactors, which will allow Daisy Lab to move from lab-scale fermentation to large-scale production. These bioreactors will be instrumental in the purification and production of dried proteins, which can be used in traditional dairy products. 


Recognizing innovation 

As Daisy Lab continues its upward trajectory, the team has also been recognized for their innovative work. Co-founder Emily McIsaac recently took home the prestigious North Harbour Club Innovation Award, securing a $30,000 prize for their groundbreaking research and became a finalist in the KiweNet Research Commercialization AwardDaisy Lab is now actively fundraising to build its first pilot facility, which will mark a new phase in the commercialization of animal-free dairy proteins. INFORS HT is proud to support Daisy Lab as they prepare to scale their operations and continue their mission to reshape the future of dairy. 

 

INFORS HT: Partnering for success 

At INFORS HT, we are excited to continue partnering with Daisy Lab as they expand their use of bioreactors to meet their growing production needs. With a focus on innovation, flexibility, and reliability, INFORS HT bioreactors are designed to support groundbreaking research and development in fields like precision fermentation. 

Learn more about how INFORS HT bioreactors can support your research

Did you like this article?Leave us a rating!

1
2
3
4
5
Average: 5/5

Comments(0)

Related articles

Blog
23 Oct 20249 min read40
Optimizing HEK293 cell cultures for gene therapy applications: the role of incubator flexibility

Gene therapy is a promising approach for treating various genetic disorders and diseases. A critical component of gene therapy is the production of viral vectors, which serve as delivery vehicles for therapeutic genes. Human Embryonic Kidney 293 (HEK293) cells have become a widely used platform for viral vector production due to their efficiency in transfection and ability to support viral replication. However, optimizing HEK293 cell cultures for large-scale production of viral vectors remains a challenge in making gene therapies more accessible and cost-effective.

24 Jun 20244 min read52
Transforming bioprocess research and development with INFORS HT bioreactor system design

Discover how INFORS HT’s bioreactor systems enhance bioprocess R&D for the Agro-Biotechnology Institute. Explore their streamlined operations and optimized yields. An interview-style article with Dr. Siti Rokhiyah PhD., Head of Bioreactor Unit at the Agro-Biotechnology Institute (ABI), National Institutes of Biotechnology Malaysia (NIBM) in Malaysia.

17 Jun 20244 min read4,50
From classrooms to pilot production: leveraging INFORS HT innovations for bioprocess scale-up

Discover how INFORS HT bioreactors and services have supported bioprocess education and research at Universiti Sains Malaysia (USM). Joo Shun TAN (陈裕声), Associate Professor, shares insights on leveraging Minifors, Multifors, and Techfors bioreactors to enhance teaching, research, and scale-up processes.

23 Oct 20249 min read40
Optimizing HEK293 cell cultures for gene therapy applications: the role of incubator flexibility

Gene therapy is a promising approach for treating various genetic disorders and diseases. A critical component of gene therapy is the production of viral vectors, which serve as delivery vehicles for therapeutic genes. Human Embryonic Kidney 293 (HEK293) cells have become a widely used platform for viral vector production due to their efficiency in transfection and ability to support viral replication. However, optimizing HEK293 cell cultures for large-scale production of viral vectors remains a challenge in making gene therapies more accessible and cost-effective.

24 Jun 20244 min read52
Transforming bioprocess research and development with INFORS HT bioreactor system design

Discover how INFORS HT’s bioreactor systems enhance bioprocess R&D for the Agro-Biotechnology Institute. Explore their streamlined operations and optimized yields. An interview-style article with Dr. Siti Rokhiyah PhD., Head of Bioreactor Unit at the Agro-Biotechnology Institute (ABI), National Institutes of Biotechnology Malaysia (NIBM) in Malaysia.

17 Jun 20244 min read4,50
From classrooms to pilot production: leveraging INFORS HT innovations for bioprocess scale-up

Discover how INFORS HT bioreactors and services have supported bioprocess education and research at Universiti Sains Malaysia (USM). Joo Shun TAN (陈裕声), Associate Professor, shares insights on leveraging Minifors, Multifors, and Techfors bioreactors to enhance teaching, research, and scale-up processes.

We care about your privacy

We use cookies to improve user experience. We analyse our traffic, we personalise content and ads on our website, and we provide social media features. Certain cookies are necessary for our website to work properly and to enable you to use its features. With your consent, we also use analytics cookies to improve our website and marketing cookies to display advertisements and content on our website. 
Cookie settings